Newsroom | 4185 results

Sorted by: Latest
Stem Cells
-

Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research

LEIDEN, Netherlands--(BUSINESS WIRE)--Ncardia launches first-of-its-kind iPSC-derived non-human primate cardiomyocytes to advance cardiac safety research....
-

Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), along with parallel regulatory filings in the United Kingdom, Europe, Serbia and Australia, to initiate a Phase 2 clinical trial of SAT-3247 in ambul...
-

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing of a $53 million financing from its existing syndicate of top-tier investors. The financing will support Ensoma’s recently initiated Phase 1/2 clinical trial for EN-374 in X-linked chronic granulomatous disease (X-CGD) and support key clinical readouts, while continuing to expand and refine the pote...
-

Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease

BERLIN--(BUSINESS WIRE)--Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for PD. At the same time, first European participants have been randomized in REGENERATE-PD, a Phase II clinical trial of AB-1005, an investigational gene therapy. Both therapies are focused on treating moderate-stage PD and are...
-

Abselion Introduces Protein G Total Antibody Quantification Kit

CAMBRIDGE, England--(BUSINESS WIRE)--Abselion launches Protein G Total Antibody Quantification Kit enabling quantification of a broad range of IgG subclasses and species on Amperia....
-

No Difference in Transplant Outcomes Seen for Patients Unlikely to Find a Matched Unrelated Donor When a Donor Search Prognosis Strategy is Used

MINNEAPOLIS--(BUSINESS WIRE)--A study by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) found that a donor search prognosis-based strategy helps physicians move patients with blood cancers and other blood diseases to hematopoietic cell transplant (HCT) faster, resulting in similar transplant success regardless of likelihood of finding a matched unrelated donor (MUD). Investigators from the consortium of U.S. transplant centers, CIBMTR® (Center for International Blood and Marr...
-

Corner Therapeutics Appoints Biotech Pioneer John Maraganore as Strategic Adviser

WATERTOWN, Mass.--(BUSINESS WIRE)--Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, today announced that biotech pioneer John Maraganore, Ph.D. has joined the company as a strategic adviser. Dr. Maraganore will advise Corner on corporate strategy, business development, and the advancement of its dendritic cell-initiated T cell engineering (DCITE) platform with a goal of developing its pipeline of novel immunotherapi...
-

Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q’s Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announces multiple strategic technology partnerships to advance the Cell Q™, the first fully automated quality control testing platform purpose-built to match the commercial-scale throughput for cell therapy manufacturing. Cellares is unveiling these partnerships ahead of the 10th Annual CAR-TCR Summit, where it will, for the first time, present drug product release da...
-

Luxa Biotechnology Announces Publication in Cell Stem Cell Describing Positive Clinical Results for First-in-Human Clinical Trial for Dry AMD Therapy

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), today announced the publication of Phase 1/2a clinical trial results in a paper titled "Safety and Tolerability of RPE Stem Cell-derived RPE Transplantation in Patients with Dry Age-related Macular Degeneration: Low Dose Clinical Outcomes" in the journal Cell Stem C...
-

Nu-Tek BioSciences Awarded EcoVadis Status for Second Year, Reinforcing Commitment to Sustainable Innovation

MINNETONKA, Minn.--(BUSINESS WIRE)--Nu-Tek BioSciences, the market leader in plant-based peptones and yeast extracts for the biopharmaceutical industry, has been awarded the Bronze designation 2025 by EcoVadis for the second year. This distinction places Nu-Tek among the top 35% of companies evaluated by EcoVadis and underscores its ongoing commitment to environmental stewardship and responsible business practices. EcoVadis assesses companies across key sustainability criteria, including enviro...